Rigel Pharmaceuticals Q2 2024 GAAP EPS $(0.06) Beats $(0.31) Estimate, Sales $36.841M Beat $33.419M Estimate
Author: Benzinga Newsdesk | August 06, 2024 04:50pm
Rigel Pharmaceuticals (NASDAQ:
RIGL) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.31) by 80.65 percent. The company reported quarterly sales of $36.841 million which beat the analyst consensus estimate of $33.419 million by 10.24 percent. This is a 37.03 percent increase over sales of $26.886 million the same period last year.
Posted In: RIGL